The PUMBA Gazette (August Edition)

8/14/2019 The PUMBA Gazette (August Edition)

1/8

1


2/8

2

THE EDITORIAL

Address,

He who has health has hope and he who has hope has

everything. The primary concern in this hectic life today is

health and more people are becoming health conscious.

With increasing level of awareness in this regard the

masses do not have much time to visit a physician. This

eads to more and more people catering in to the OTC

drugs which contribute a lot to the pharmaceutical sector.

There are more than 100,000 drugs that fall in this category.

Owing to this we have decided to dedicate the August issue

of our monthly newsletter to Over the Counter medicines.

An extensive study has been carried out by the students to

analyze the reasons for side effects of pain killers and

suggesting ways to combat the same.

We also bring to you an exclusive interview with Mr.

Madhukar Kurtkoti an eminent person from the

Pharmaceutical industry with over 35 years of experiencehrowing light related to marketing of OTC.

An article related to Packaging with respect to these drugs

s also included.

n the BT news section we take upon the various aspects of

he Mashelkars report with respect to ever greening of

patents.

We also present before you one of the 12 part series of

notable CSR initiatives. The article titled Back to Societyhis time covers the SPARSH initiative by Torrent Group.

Along with this section on PUMBA and its latest happenings

has been included.

Your feedback and Suggestions are welcome at

[email protected]

Reading maketh a full man, conference a ready man,

and writing an exact man - Francis Bacon

Sincerely Yours,

Chief Editor: Queeny Bubna, MBA-BT (Sem III)

The PUMBA Gazette Team)

The detailed project report shall be provided on

enquiry. Kindly send in your enquiries at

[email protected])

CONTENTS

Cover Story 3

--Cide ing Side Effects Articles/Analysis 4

--Pack in your senses

Back to Society 5

--SPARSH Initiative by Torrent Group

BT News 6

--Going GreenThe Patent Way

Candid Talk 7

--An Interview with Mr. Madhukar Kurtkoti

PUMBA News 8

--Dr. (Prof.) Sangvikars Selection for University Exchange

Program

-- Dr.(Capt) C.M. Chitale appointment to YASHADA

--Dr. S.V. Kapres Lecture
mailto:[email protected]:[email protected]


3/8

3

Cideing side effects

The over- the-counter and prescription painkillers also known as

he non-steroidal anti-inflammatory drugs or NSAIDs are one of

he most widespread used drugs. The number of over-the-counter

OTC) medications is increasing as more prescription medications

are being designated the OTC status and there are over 100,000

such drugs. Despite their extensive use it is observed that it is

often used inappropriately and an alarming number of people are

gnorant of the potential side effects that result thereafter. So a

survey was carried out by the students of PUMBA to gauge the

awareness of side effects of painkillers among the consumers. For

his around 400 consumers as well as 100 chemists were

surveyed in Pune.

The key findings of the survey were astonishing as majority of

middle age people use these drugs irrespective of its side effects

and many of them consider it an easy way out to deal with pain

and avoid visiting a physician. Patients may also inadvertently take

multiple OTC drugs containing the same active ingredient, which

could lead to an overdose or increased side-effects. In other

cases, patients may take more than the recommended dose of a

drug, as they do not read or understand the directions or theysometimes choose to ignore them, believing that a higher dose

should be more effective. The anomaly lies in the fact that it is the

educated and working class group of middle age taking these

steps. A majority of them are unacquainted with the names and

side effects of these drugs when not taken in a right fashion. They

end to overlook the fact that the same drugs when used in the

correct manner would be much more beneficial.

RESULTS AND DISCUSSIONS

The average usage of painkillers age-wise was found to be as

epresented in the chart below. Maximum consumption was found

o be amid the age group of 25 to 40 years. As revealed by thesurvey this category resorts to self medication nearly 12 times in a

month. The most widely used painkillers were established as

paracetamol, nimusulide, diclofenac and ibuprofen.

Around 50% of the consumers surveyed did not consult any doctor

before using a painkiller. According to the chemists surveyed, 43%

of the consumers asked for painkillers without any prescription.

Also approximately 63% did not enquire about the side effects of

he medicine in question.

When enquired about the understanding of side-effects due to

painkillers, 36% were not aware of any while 46% of those

nterviewed had heard of them but were not fully informed. Hardlyany consumers were disinclined to use painkillers due to their

side-effects.

SUGGESTIONS & RECOMMENDATIONSLong term use of NSAIDs in high doses may cause an increased

risk of gastrointestinal complications ranging from stomach pain to

ulcers, hemorrhage etc. Thus an awareness regarding this has to

be created amongst the population as well as the physicians to

encourage the correct dosage and usage of the painkillers. For

this the followings steps can be taken:

1. Problems resulting from such inapt usage of OTCs should be

constantly highlighted in CMEs, journals, etc, so that the

physicians convey the same to those who do consult them before

using a NSAID. This population was found to be 23% of the

sample covered.

2. Since most of the NSAIDs are OTC drugs, it should be noted

that most chemists are ignorant about this and hence an attempt

should be made to educate the chemists regarding the adverse

effects of the same.

3. Education programs as well as workshops should be carried out

for the patients using painkillers to make them aware of the risks

associated with it.

4. In USA a campaign was carried out in 2003 known as

R.E.D.U.C.E (Risk Education to Decrease Ulcer Complications

and Their Effects from NSAIDs) by AGA (American

Gastroenterological Association), funded by Pfizer. Similar

campaign should also be initiated in India in cooperation with the

major Pharmaceutical companies.

5. Boards and Hoardings, highlighting serious complicationsarising from unrestrained usage of NSAIDs, sponsored by

pharmaceutical organizations should be displayed in hospitals,

government dispensaries, and clinics of private practitioners.

6. Companies can also publish literature to inform laymen of the

right way to take these drugs in order to increase efficacy. As most

OTCs are mouth to mouth marketed, an initiative like this would

increase trust and loyalty in consumers and thereby increase

market potential.

Compiled by: Dipali Bobade, Nidhi Nirmal Rutuja Patil, Smita

Rathod, Soumya Gupta & Sourabh Dhopade (MBA-BT, Sem III )

Mentor: Pratiksha Singhal (alumnus MBA BT-2009 currently

working in WNS Global Services as Junior Analyst)
http://en.wikipedia.org/wiki/Overdosehttp://en.wikipedia.org/wiki/Side-effectshttp://en.wikipedia.org/wiki/Side-effectshttp://en.wikipedia.org/wiki/Overdose


4/8

4

Pack in your senses

Packaging undoubtedly plays a critical role in any pharmaceuticalproduct, be it capsules, tablets, syrups or medical devices.Products are packaged considering numerous factors such asransit, weather, time and cost for maintaining their safety, stability

and integrity; long after they leave the manufacturing unit. Itprovides companies one of the most important instruments forheir brand protection. In view of the fact that competition isncreasing day by day, companies constantly aim towardsdifferentiating their products to ensure consistency of growth.

Though highly significant pharmaceutical packaging in Indiaemained invariable but of late smart packaging and its direct

correlation with the products marketing is gaining importance inhis sector. A lot can be done in packaging in terms of the

positioning of a product, as it is the face of the brand. There arealso pass-offs which affect a brand. If there is a reputed brandmarketed in a particular category, then there are a host of brandsavailable which just mimic the packaging format or maybe thecolor of the blister of that principle brand. One cannot identifyhese from the original ones as they are genuine products comingrom companies with a proper manufacturing license. What these

companies try to do is ride on the brand image of the leader brandhat has been created over a number of years. This ends up

affecting the sales of the main brand tremendously. To avoid this,companies can make provision for distinctive packaging in order togain an upper hand in the market.

Earlier the only function of packaging was to carry the product andkeep it safe until consumption. However of late it has beenobserved by manufacturers that they can build credibility and theuser-product bond if consumers could 'SEE' the product. Thevisual stimulus can never be ruled out, not at least for somethingwe ourselves consume. For instance transparent capsules withcolorful beads inside are not only attractive and appealing but alsomore reliable. A syrup in a transparent glass bottle is preferred aot more than the amber color bottle. Transparent blister packs arepreferred more than the aluminum strips. As companies arebecoming more aware of this imperative fact, they are also

esponding to the need and are no longer hiding medicines behindopaque covers.

Another important aspect again revolving around visualization ishe color of the product. Color branding is very important, more soor OTCs in India and across the globe. It is far more essential inhe developing and underdeveloped countries as people connecto a product with its color and design in absence of formal

education. In fact OTCs and prescribed products should bedifferentiated on grounds of packaging also and there should be aclear demarcation among the two.

In OTC marketing, it is very vital that the patient gets the desiredeffect the company is talking about. The information related shouldbe clearly written in the absence of a physician to provide theguidelines. The enclosure should also contain a note explaininghe harmful effects of over-dosing and improper intake. For OTC

drugs, the packaging should establish a connection with theconsumer as in case of FMCG products. Any product intended forchild consumption will instantly reflect packaging content featuringvibrant colors that appeal to the youngsters mind. In Internationalmarket this scenario can be ordinarily experienced. For example,an anti-AIDS pack was accompanied by a toothbrush to remindhe patient that the medicine had to be taken twice a day, like

brushing teeth.

There are different consumer conditions, different age groups orlifestyle requirements that need different packaging solutions andif these solutions are met effectively then it establish a sense ofcommitment between the product and its consumer group. Toexemplify, arthritic patients have a set of requirements specific tothem which can be taken care of via some simple modifications inpackaging. Tylenol in USA launched a special yet simple pack forarthritis patients. The toughest task for an arthritic is to open a lidof the bottle containing medicine as they do not get enough grip to

turn open the lid. Tylenol launched a pack with a hole in cap. Apatient was expected to push a pencil in it and push it open. Suchendeavor not only makes things easy functionally for the patientbut also add to the goodwill of the company.We can also observe utility of packaging of MWV HealthcaresCerepak. Its smart package is mainly used in clinical trials. Itrecords the date, time, and location of each tablet or pill as it isremoved from the package. This data can be quickly downloadedinto a computer for analysis by the patient or healthcare provider.The system also enables interaction with the patientit can recordside effects or symptoms, as well as discreetly prompt the patientto take the medication using light, sound, or vibration.

In todays era understanding the latent need of the consumer anddesigning a product accordingly is what will help companies to gothe extra mile. For example, Diabetes sufferers who are on insulintherapy at times need to carry the medication along with themwherever they go. Thus Novo Nordisk's drug Novopen, whenlaunched, fulfilled this need perfectly as the pack looks just like apen and can be carried anywhere. Such packaging has theadditional potential to take away the stigma of a disease likediabetes.

The other important factor which packaging deals with iscounterfeit drugs. Though pharmaceutical companies extensivelyuse holograms for this purpose but it has certain limitations.Firstly, most of the patients lack the understanding or awarenessto look for a hologram and also it is practically impossible to createawareness to see hologram of each drug before purchasing it.

Secondly, in some cases even holograms are copied. Thus insuch cases, color of the packaging also plays vital role in limitingcounterfeiting. If there is a product which has a unique color thatcan't be copied it gets registered in the mind of the patient, then itbecomes a very strong feature with which a person can associateand recognize the product when he goes to buy it. In addition tothis, pharmaceutical packaging must adhere to stringentregulations that require material traceability, good manufacturingpractices (GMPs), consistent quality, product protection, and oftenchild-resistance. Pharmaceutical companies must thereforeconsider their product on all such parameters and come up with anOptimal packaging complex to utilize all advantages of effectivepackaging.

Compiled by: Ashish Mishra (MBA- BT, Sem III)


5/8

5

Back to society- CSR initiative by

Torrent Group

Community welfare initiatives by any organization bringabout remarkable changes in the society and in the longerm prove to be a significant investment for the companytself. One such initiative is undertaken by the TorrentGroup of companies, a multifaceted & dynamic group ofcompanies. The organization, one of its kind, strongly

believes that every bit of success should be shared with thesociety that it exists in. To make a difference in the qualityof life at Ahmedabad & Surat in the areas of Health,Education, Public Amenities and Community Development,Torrent Group came out with a unique CSR initiativeSPARSH.

Sparsh is making a difference in improving quality of life inslum areas by increasing the percentage of school goingchildren and spreading awareness about diseases andeducation among them. This is very essential in a companyike India where a huge population resides in the slums andmost of children miss the basic amenities of life. Upgrading

of Municipal schools, Government hospitals and publicparks/gardens, beautification of the surroundings byplanting trees are among some of their CSR initiatives.

Health & Education: In 2005, 140 employees werenvolved in an awareness program about education, health,and hygiene though door to door canvassing; film shows,putting up of posters and distribution of handbills, healthbooklets in 3 major slums. Also Torrent provided teachingaids in Urja Vidyalaya (school of Torrent Power AEC Ltd.)ike creation of computer laboratory, assembly hall &classroom.

Training programs for municipal school teachers wereorganized with an objective to enhance the Primary SchoolTeachers teaching skills.

A health check-up camp was arranged for 641 students ofUrja Vidyalaya and 38 children residing in township wereexamined by the Group doctors.

n 2006, torrent initiated the up gradation of general medicalacilities in ESIS hospital and also renovated 5 municipal

schools. Under "Jeevan No Ujaas" Program, slums inSabarmati area were 100% electrified. This was a realachievement as there are still many slums in other parts ofhe nation who have not received a streak of electricity inheir entire existence.

COMMUNITY DEVELOPMENT &PUBLIC AMENITIES

Another aspect which the organization keeps in mind isregarding A Swachchta Abhiyaan was undertaken to clean,mprove, and beautify roads and streets of Sabarmati. Alsot undertook an extensive task of cleaning of public waterstorage tanks including 5 underground tanks.

n 2005 Torrent group also organized tours for members ofSenior Citizens Club to Torrent Power AEC GenerationPlant at Sabarmati, Torrent Power AEC Fly Ash Treatment

Pond, it also worked to enhance facilities for over 150members of Senior Citizen's club including by providingbooks to improve the quality of library.

Torrent promoted safe and efficient usage of electricity byorganizing exhibitions on electrical safety and generalsafety, presenting the knowledge and requirements oneffective and safe usage of electricity at 3 schools inSabarmati for local residents and school students.It also established and promoted institutions like U.N. Mehta

Institute of Cardiology and Research Centre at Ahmedabad.The health check-up programmes organized in Schools oftorrent power AEC ltd aimed at strengthening the employeeemployer relationship and promoted welfare of employee.

The tours organized for senior citizens to Torrent PowerAEC Generation Plant at Sabarmati, built goodwill amongsenior citizens and made an impact about the company aswell.

CSR initiatives are a very small step towards the strategicdevelopment of a company but a giant leap in improving thelife of people.

Special Thanks to: Mr. Sandeep Yeshi & Mr. Gautam Bhatt

(Torrent Pharmaceuticals Ltd.)

Compiled by: Nivedita Singh & Snigdha Sinha (MBA-BT,

Sem III)


6/8

6

Word-of-Mouth plays a vital

role.

Mr. Madhukar Kurkoti has over 35

years of experience in the

Pharmaceutical Industry at senior levels

in diverse areas like strategic planning,

marketing, new product development,

company turnaround, and merger&

integration management. Some of thecompanies he worked with are Torrent

Pharmaceuticals Limited, Reckitt Piramal

Limited, Nicholas Piramal India Limited

(NPIL), Redikure Medrox Nigeria Limited,

& Abbott Laboratories. Sir is associated as visiting faculty with

PUMBA for the MBA- BT program.

The PUMBA GAZETTE team managed to get an insight into the

OTC scenario in an exclusive interview with Sir.

Q1.What according to you is the drive for selecting an OTC

product?

Consumers are guided by various factors however the type of

consumer accounts for the major drive. Why people choose an OTC

product is different for the urban and for the rural areas.n rural areas the issue is lack of access to a doctor and health

services in immediate vicinity. Besides most people do not pay

attention to minor ailments that may keep them away from farming or

any other money earning activity as there exists immediate need to

get back to work.

n the urban areas it is due to the busy lifestyle, which prevents people

rom spending endless hours in a doctors clinic. In most cases the

nitial demand is triggered by a doctors prescription. And then the

approach is generally I have used this earlier for similar symptoms. Id

herefore try it myself. For minor ailments a friends advice is also

considered vary valuable. Word-of-Mouth plays a vital role.

Q2.What are the main promotional strategies adopted for OTCproducts?

n addition to usual media like TV, Newspapers, Health Magazine

advertising companies use merchandising and trade promotion to

enhance revenues. Some companies use the packaging itself as the

silent seller.

Special in-store displays by the distributors salesmen are also

adopted by some companies.

The real key however is positioning. The same product can be

positioned as the first line of treatment, or the first line of defence or

he first step in prevention. Or, you could have a more serious

positioning when every other remedy has failed

Product differentiation is critical. The product has to work along all the

dimensions functionality, emotions and the social dimension.

Q3. Do companies opt for difference in marketing strategies of

OTC in developed developing and underdeveloped countries?

What are the major challenges faced?

The evolutionary stage of a market forces companies to adopt varying

strategies. It is also a function of the marketing environment,

egulatory challenges, sophistication and maturity levels of markets

and consumers. All these factors are further complicated by social

attitudes, work ethic and concept of urgency and time. Then there are

ssues of logistics and economies of distribution penetration.

Packaging, unit-of use, Cost per dose, money needed to be put down

also pose challenges.

n the advanced markets the battle is for shelf-space. In the developed

world there is the OTC expense being borne out-of-pocket and Healthnsurance does not pick up the tab.

n the developing world the challenges is of spurious and pass-off

products. In several developing markets home-remedies pose a

competitive challenge. For example in India more than 30 % of

consumers use a home remedies. This would also be true for other

countries with a well developed system of indigenous medicine e.g.

China, Indonesia, Sri Lanka etc.

Q4.What role does the pricing play with respect to OTC

products? Do companies prefer to adopt a competitive pricing

strategy?

All OTC products have to deliver on the value proposition first. Like

prescription products even for OTC products the truism A product that

a cost more per unit is also the one that sells more units will hold.

Pricing would be important in the context of the alternatives available

and the value being offered. In several cases need drives value. For a

person with a pounding headache, immediate relief is vital not the

price. Price in strategy terms has to be viewed as an integral part of

the total offering and brand experience rather than as a stand-alone

strategy.

The true differentiator for OTC products is the branding capability.

Q5.With increasing number of companies going global how do

they handle packaging related concerns? Is there any color

coding or font size guide followed?

Companies that operate globally ensure that they comply with the

regulatory and legal framework of every single country where they

operate. Labelling and packaging requirements are clearly stated for

most countries. For example all francophone countries mandate

companies to have a red box for prescription only schedule drug. In

India a product that has ingredients of animal origin need a brown box

with a brown dot.

In several countries a bi-lingual or a multi lingual packaging becomes

an imperative. One has also to keep the social meaning of color for

packaging design. The graphics used also have to be tested for any

adverse connotations. In terms of bar coding the universal packaging

code has to be followed.

Q6.Chinas demand and the production for OTC has grown at a

fast pace in the last decade. Should India perceive China as a

potential threat to OTC market?

OTC business depends entirely on brand building capabilities. A

strong brand in China means nothing in the context of India. Brand

strengths are not transferable across borders. For example the brand

LIPOVITAN (A product containing Taurine, some B-Complex factors

and positioned as an energy drink) is a very powerful brand in Hong

Kong. In India it is REDBULL that has made an impact.

In addition the brand building capabilities of Indian companies are truly

world-class. The Chinese business model is based on economies of

scale, heavy subsidies, currency shoring efforts and not so much ontrue entrepreneurial grit. Dr.MOM of Unique is one of the most

recognized brands in Russia.

Q7.It has been observed that there has been a serious misuse of

OTC products across India, Bangladesh, and Nepal in the past

few years. Is there a regulatory body to regulate such matters?

I remember there was an issue of misuse of a cough syrup brand few

years back. These things are generally triggered by an overzealous

sales person out for his performance bonus or an end user who has

found off-label use for a product.

The body to regulate these issues is the drug control authorities in

each country or in a given state. The issue revolves around an

inadequate administrative apparatus than an issue of political will.

Compiled by: The PUMBA GAZETTE Interview Team


7/8

7

Going Green-The Patent Way

The pharmaceutical industry channels an important proportionof total research in most developed countries. Organizationsare driven to this field as medicines and their method ofproduction are commonly protected by patents. The hugeunds thus invested are only compensated for in the duration ofpossession of patent. These patents remunerate aresearchers innovation stimulating further research anddevelopment of medicines from which we all benefit.However in recent years, pharmaceutical companies havebeen accused of devoting their resources mainly to minormprovements over existing medications. Globally, most MNCsry to continuously extend their product patents by institutingsmall chemistry-related changes. In trade circles this is knownas Evergreening. Evergreening is usually done to extend thentellectual monopoly privileges, particularly over highlyprofitable (either in total sales volume or price per unit)blockbuster drugs.

In developing nations like India, such concepts would drawmulti facet reactions. It can lead to higher prices as companiescan charge whatever they wish due to their evergreenmonopoly over a patent. There are a large number of peopleafflicted with cancer and HIV who need inexpensive medicineso stay alive. Consequently in order to protect the interests ofhe masses the Indian Patent Act does not allow Evergreening.Section 3(d) of Indian Patent Act states that The merediscovery of a new form of a known substance which does notresult in the enhancement of the known efficacy of thatsubstance or the mere discovery of any new property or newuse for a known substance or of the mere use of a knownprocess, machine or apparatus unless such known processresults in a new product cannot be patented It stipulated that if

a pharmaceutical company wanted a patent for anmprovement on an already existing drug, it must show that themprovement actually made the drug more effective. Howeverogical it may seem, it is clearly not in the interests of themultinational corporate lobby.

In the recent times, there is a section of the industry trying topersuade the government to allow Evergreening. The issue iswhether it would be compatible with the World TradeOrganizations Trade-Related Aspects of Intellectual PropertyRights (TRIPS) agreement to limit the grant of patents forpharmaceutical substances to new chemical entities or newmedical entities involving one or more inventive steps only The

argument is that molecules are patented very early during theprocess of drug discovery, but unique clinical characteristics orbenefits are not discovered until much later, when clinical trialsare conducted, if at all. Therefore, it is unreasonable to ask thatunique characteristics of a slightly altered molecule bedescribed at the time of the application for the patent, itself. Agovernment-appointed committee on patent laws, headed Dr.R.A.Mashelkar, former chief of CSIR, favoured the grant ofpatents to all incremental innovations made to a drug, but noto light hearted Evergreening, in order to make the IndianPatents Act TRIPs compliant. Although the report ultimatelypermitted most forms of Evergreening still the questionremains unanswered regarding the take on it.

Contrary to the claims by many drug companies increasedintellectual property protections have not fostered moreinnovation for better treatment. Despite increased spending onR & D over the past decade, the number of new drugapplications has not significantly increased. Further, 2/3rd of the

new drug applications are mere modifications to the existingdrugs. This process of making slight changes to drugs is oftenused to prolong the life of patents in order to sustainmonopolies. With revenues exceeding $1 bn annually for manydrugs most pharmaceutical companies have been moreinclined to pour funds back into blockbuster drugs that canyield further profits rather than more innovative treatments. Sohaving failed in the original attempt to prevent flexibilities beingincorporated in the TRIPS agreement, now the developedcountries under pressure from their pharmaceutical industrylobby have turned their eye on World Intellectual PropertyOrganization (WIPO) to modify the original provision of TRIPS.Ever greening, if permitted under Section 3(d) of the Indian

Patent Act then it would encourage renewal of patents andblock entry of low-priced generic drugs into the market. Thismay prove to be a major setback to the Indian pharmaceuticalcompanies as a majority of their revenues come from genericversions of patented drugs. It would also lead to a precipitousrise in the prices of life-saving drugs and render theminaccessible to the poor. To cite one instance, Leukaemiapatients could see the cost of their medication increase around12 times.

On having a glimpse further the concept is not necessarily adisadvantage to India. For example, if Evergreening ispermitted, Indian companies may be able to develop andpatent incremental advances on patented drugs and many new

drugs might enter the Indian markets. This could be aided bythe fact that working on already existent molecules is not asdifficult as stating a new molecule all together as it requiresless investment. Also there is immense scope in this field touse Bioinformatics as companies can use molecular modellingand drug designing principles to obtain better results. A denovo drug would be difficult as compared to the betterment ofan existent molecule. At the same time the MNCs would retainthe patent for the original drugs and earn huge profits which inturn would be invested in the discovery of new molecules. Thiswould again open up scope for the generic companies downthe line and give them more business for the future. So in orderto ensure that people have access to medicines at affordableprices what India needs to do is have laws that will increasethe benchmarks or threshold limits while granting patentswhich is the ultimate purpose of Section 3(d) of Indian PatentAct.

Compiled by: Nikhil Goyal, Vandita Javali.(MBA-BT, Sem III)


8/8

8

PUMBA NEWS

t is with immense pleasure and pride that we inform Dr. B.V.

Sangvikar , Head , DMS( PUMBA) has been selected under

the exchange program Academic Mobility Program at

Polytechno di Milano

University, Italy . This

program is undertaken by

the European Commission

Erasmus Mundus whichis a research collaboration

involving ten Universities

each from Europe and

India. Dr. Sangvikars area

of expertise is Retail

Management, and he is

among the chosen few to

be selected for this particular venture owing to his vast knowledge

and huge experience in the line. His forte would be on latest

rends in this field and he would be working with the Department of

Management & Industrial Economics of the University, Milan.

nother feather in the cap of Pumbas achievement is thatour Dean Dr.(Captain) C.M.Chitale has been appointed onthe executive body of

YASHADA(Yashwantrao ChavanAcademy of Development

Administration) for 3 years.Some of the objectives of theacademy as listed in the MoAare to serve as an apex instituteor the collection and

dissemination of informationegarding development

administration and to provideconsultancy services indevelopment and publicadministration. There are 8 members in the Committee who wouldogether be looking after the working of this body and Sirepresents the Pune region.

n July 18th

PUMBA campus was graced by one of the mosteminent leaders of the Biotechnology Industry,Dr.S.V.Kapre, Executive Director, Serum Institute ofIndia. He introduced the newly inducted students to the

highly potential Vaccine

Industry. Dr. Kapre talkedon the transition of theBiotechnology Industrythroughout the years. Heemphasized on the roleplayed by Indiancompanies in the globalVaccine industry andgave a brief introductionto the general processand financials of aVaccine launch. Last butnot the least, Dr. Kapre

enlightened the fresh minds of 2009-11 Batch and encouraged

hem to excel in their future. An interactive session followed inwhich Dr. Kapre answered the queries by students.

I

A

O

The PUMBA Gazette (August Edition)

Documents

Transcript of The PUMBA Gazette (August Edition)